Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:51:49.426Z.
Calculation as of: 2026-10-06T15:51:49.426Z.
Quote observation: 2026-10-06T15:50:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$109.16M
Price/OCF Ratio
N/A
TTM Avg
8.98
3Y Avg
8.98
5Y Avg
8.98
Market Cap
$109.19M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108.67M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.08M
Price/OCF Ratio
142.20
TTM Avg
45.05
3Y Avg
23.19
5Y Avg
15.20
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $110.67M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.49M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $109.16M | N/A | 8.98 | 8.98 | 8.98 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $109.19M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.61M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.67M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.08M | 142.20 | 45.05 | 23.19 | 15.20 |
| MaxCyte, Inc. (MXCT)vs › | $113.55M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.51M | 2.55 | 3.01 | 10.71 | 28.96 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
